Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Apellis Pharmaceuticals revenue
Apellis Pharmaceuticals's revenue is $781.4 million.
What is Apellis Pharmaceuticals's revenue?
- Apellis Pharmaceuticals's revenue growth from 2020 to 2024 is 211.74%.
- Apellis Pharmaceuticals has 200 employees, and the revenue per employee ratio is $3,906,835.
- Apellis Pharmaceuticals's peak quarterly revenue was $250.0M in 2020(q4).
- Apellis Pharmaceuticals peak revenue was $781.4M in 2024.
- Apellis Pharmaceuticals annual revenue for 2023 was 396.6M, 425.83% growth from 2022.
- Apellis Pharmaceuticals annual revenue for 2024 was 781.4M, 97.02% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Apellis Pharmaceuticals historical revenue
Apellis Pharmaceuticals's peak revenue was $781.4M in 2024. The peak quarterly revenue was $250.0M in 2020(q4).
Apellis Pharmaceuticals's revenue increased from $250.6m in 2020 to $781.4M currently. That's a 211.74% change in annual revenue.
Apellis Pharmaceuticals annual revenue
Apellis Pharmaceuticals annual revenue over time
| Fiscal year / year | Apellis Pharmaceuticals revenue |
|---|---|
| 2020 | $250.6M |
| 2021 | $66.6M |
| 2022 | $75.4M |
| 2023 | $396.6M |
| 2024 | $781.4M |
Rate Apellis Pharmaceuticals' financial transparency
Apellis Pharmaceuticals annual growth
Apellis Pharmaceuticals saw the greatest revenue growth in 2022, when revenue increased by 13.31%.
Apellis Pharmaceuticals had the lowest revenue growth in 2021, when revenue changed by -73.44%.
Apellis Pharmaceuticals annual growth rate over time
| Year | Apellis Pharmaceuticals growth |
|---|---|
| 2021 | -73%↓ |
| 2022 | 13%↑ |
| 2023 | 426%↑ |
| 2024 | 97%↑ |
Apellis Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Apellis Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | $646,000 | $250.0M |
| 2021 | - | $623,000 | $5.7M | $60.3M |
| 2022 | $14.4M | $16.3M | $22.1M | $22.7M |
| 2023 | $44.8M | $95.0M | $110.4M | $146.4M |
| 2024 | $172.3M | $199.7M | $196.8M | $212.5M |
Apellis Pharmaceuticals jobs nearby
Do you work at Apellis Pharmaceuticals?
Did Apellis Pharmaceuticals meet its revenue projections?
Apellis Pharmaceuticals financial information
| CEO | Cedric Francois |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 200 |
| Date Founded | 2008 |
| Headquarters | Waltham, Massachusetts |
| Number of Locations | 2 |
| Revenue | $781.4M |
| Net Income | -$652,172,000 |
| Gross Proft | $663.6M (2024) |
| Tax Rate | -0.0% |
| Total Assets | $760,217,000 |
| Ticker | APLS |
Apellis Pharmaceuticals jobs you might like
Apellis Pharmaceuticals financing
Apellis Pharmaceuticals received early financing of $1.7M on 2010-05-21.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $1.7M | 05/2010 |
| Series A | $3.0M | 06/2011 |
| Series Unknown | $17.8M | 07/2013 |
| Series Unknown | $6M | 08/2013 |
| Series C | $33M | 12/2014 |
| Series D | $47M | 02/2016 |
| Series E | $60M | 08/2017 |
Apellis Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Mammoth View (KSTC) | Series Unknown |
| Mammoth View (KSTC) | Series A |
| Masa Life Science Fund | Series A |
| Health Ventures LLC | Series A |
| Pegasus Capital Advisors | Series A |
| Mammoth View (KSTC) | Series Unknown |
| Morningside Private Investors | Series C |
| Aju IB Investment | Series C |
| Morningside Group | Series D |
| Aju IB Investment | Series D |
| Cormorant Asset Management | Series D |
| Hillhouse Capital Group | Series D |
| venBio Partners | Series D |
| Epidarex Capital | Series D |
| Sectoral Asset Management | Series E |
| Vivo Capital | Series E |
| SOFINNOVA INVESTMENTS INC | Series E |
| Cormorant Asset Management | Series E |
| Morningside Ventures | Series E |
| F-Prime Capital | Series E |
| Clough Capital Partners | Series E |
| venBio Partners | Series E |
| Epidarex Capital | Series E |
Apellis Pharmaceuticals competitors
Apellis Pharmaceuticals's top competitor, Kodiak Sciences, earned an annual revenue of $43.0B.
Apellis Pharmaceuticals's smallest competitor is Kv1.3 Therapeutics with revenue of $110.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Cara Therapeutics | - | $7.1M | 84 | - |
| Eidos Therapeutics | - | $26.7M | 20 | - |
| Inozyme Pharma | - | $2.2B | 20 | - |
| Stealth BioTherapeutics | - | $21.1M | 52 | - |
| Kodiak Sciences | - | $43.0B | 28 | - |
| Arvinas Inc. | - | $263.4M | 83 | - |
| Catalyst Biosciences | - | $105.8M | 21 | - |
| Akebia Therapeutics | - | $160.2M | 324 | - |
| Akari Therapeutics | - | $1.6M | 8 | - |
| Kv1.3 Therapeutics | - | $110,000 | 5 | - |
Apellis Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Apellis Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Apellis Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Apellis Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Apellis Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Apellis Pharmaceuticals. The data presented on this page does not represent the view of Apellis Pharmaceuticals and its employees or that of Zippia.
Apellis Pharmaceuticals may also be known as or be related to APELLIS PHARMACEUTICALS, INC., Apellis Pharmaceuticals, Apellis Pharmaceuticals Inc and Apellis Pharmaceuticals, Inc.